Strs Ohio Mersana Therapeutics, Inc. Transaction History

Strs Ohio

$24.9 Billion
Q2 2024

A detailed history of Strs Ohio transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Strs Ohio holds 8,700 shares of MRSN stock, worth $16,095. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,700

Previous 2,400 262.5%

Holding current value

$16,095

Previous $10,000 70.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$2.0 - $4.45 $12,600 - $28,035	6,300 Added 262.5%	8,700 $17,000
Q1 2024 May 13, 2024	SELL	$2.16 - $5.94 $216 - $594	-100 Reduced 4.0%	2,400 $10,000
Q4 2021 Jan 24, 2022	BUY	$5.48 - $9.86 $13,700 - $24,650	2,500 New	2,500 $15,000
Q3 2021 Oct 22, 2021	SELL	$8.56 - $14.47 $1.32 Million - $2.22 Million	-153,742 Closed	0 $0
Q1 2021 Apr 23, 2021	SELL	$15.31 - $26.52 $27,558 - $47,736	-1,800 Reduced 1.16%	153,742 $2.49 Million
Q4 2020 Jan 25, 2021	BUY	$16.84 - $27.59 $1.86 Million - $3.05 Million	110,611 Added 246.18%	155,542 $4.14 Million
Q3 2020 Dec 14, 2020	BUY	$16.2 - $25.7 $538,342 - $854,036	33,231 Added 284.03%	44,931 $836,000
Q2 2020 Jul 23, 2020	BUY	$5.24 - $23.4 $61,308 - $273,780	11,700 New	11,700 $273,000
Q4 2018 Jan 23, 2019	SELL	$3.45 - $9.72 $0 - $0	0 Closed	0 $0
Q3 2018 Oct 19, 2018	SELL	$10.0 - $19.02 $69,000 - $131,238	-6,900 Closed	0 $0
Q1 2018 Apr 20, 2018	BUY	$13.56 - $18.48 $73,224 - $99,792	5,400 Added 360.0%	6,900 $108,000
Q3 2017 Oct 23, 2017	BUY	$14.8 - $18.06 $22,200 - $27,089	1,500	1,500 $25,000

Others Institutions Holding MRSN

# of Institutions

124

Shares Held

114M

Call Options Held

73.5K

Put Options Held

46.4K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $180M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account